Larazotide: The Zonulin Antagonist

An 8-amino-acid synthetic peptide (AT-1001) that blocks zonulin signaling at intestinal tight junctions — the molecular gatekeeper of "leaky gut." Studied for celiac disease and now in phase 2a for Long COVID at Massachusetts General Hospital.

🔬 Larazotide is the most clinically advanced "leaky gut" peptide. The celiac phase 3 missed its primary endpoint statistically but the safety record is clean across thousands of patient-doses, and the Long COVID trial gives it a 2026 readout window. The molecule survives where the indication shifts.

Amino-Acid Length
(Synthetic Peptide)

Phase 3 Studies
Conducted

Long COVID
Phase 2a Readout

Mechanism of Action

How It Works

🚪

Zonulin Antagonism

Zonulin is the only known human regulator of intestinal tight junctions. Larazotide blocks zonulin-induced opening of tight junctions, reducing paracellular permeability — the mechanism behind "leaky gut" theories.

🧪

Locally Active, Not Absorbed

Designed for oral administration with minimal systemic absorption. Acts at the apical surface of enterocytes. Safety profile across phase 1–3 is essentially placebo-equivalent.

🌾

Celiac Disease (Original Indication)

Adjunct to gluten-free diet. Phase 2 met endpoints; phase 3 (Innovate Biopharmaceuticals 2021) missed its primary endpoint statistically but showed favorable trends. Development pivoted.

🦠

Long COVID (Active 2026 Trial)

NCT05747534 — phase 2a randomized double-blind placebo-controlled trial at Massachusetts General Hospital. Children and adults with Long COVID. Primary completion estimated July 31, 2026.

Data

What the Data Shows

Phase 2 Celiac Trial — GI Symptom Improvement

Larazotide superior to placebo on gluten challenge

Positive

Phase 3 CeD-PRO Primary Endpoint

Innovate Biopharmaceuticals 2021

Missed

Safety vs Placebo

Across all completed trials

Comparable

NCT05747534 — Long COVID Phase 2a

MGH-sponsored, primary completion Jul 2026

Active

Other Indications Explored

NAFLD, T1D, IBD — preclinical / early clinical

Multiple

Bottom Line

Key Takeaways

✅ What We Know

8-amino-acid synthetic peptide; only known zonulin antagonist
Locally active in the gut, minimally absorbed systemically
Phase 2 celiac data positive; phase 3 missed primary endpoint
Safety profile across thousands of patient-doses is essentially placebo-equivalent
Active 2026 phase 2a trial for Long COVID (NCT05747534) at MGH
Being explored for NAFLD, type 1 diabetes, and inflammatory bowel disease

⚠️ What We Don't Know

Whether the Long COVID phase 2a will succeed (readout July 2026)
Whether the celiac program restarts with revised endpoints
Optimal dose-frequency for non-celiac indications
Whether "leaky gut" as a clinical entity benefits beyond celiac and Long COVID
Long-term safety beyond 6-month exposure data

FAQ

Frequently Asked Questions

What is larazotide?

Larazotide acetate (AT-1001) is an 8-amino-acid synthetic peptide and the only known antagonist of zonulin — the human regulator of intestinal tight junctions. It is taken orally, acts locally on the apical enterocyte surface, and is minimally absorbed systemically. Originally developed for celiac disease as an adjunct to gluten-free diet.

Is larazotide FDA-approved?

No. The phase 3 celiac trial (Innovate Biopharmaceuticals, 2021) missed its primary endpoint statistically. The molecule is currently in phase 2a for Long COVID at Massachusetts General Hospital (NCT05747534) with primary completion estimated July 31, 2026, and is being explored for other indications.

Can I buy larazotide?

Larazotide is not commercially available as a prescription drug. Some research-grade peptide vendors sell it for laboratory use only. There is no clinical pathway to obtain it as a treatment outside of trial participation as of April 2026.

How does larazotide differ from BPC-157 for gut health?

Different mechanisms. Larazotide blocks zonulin → reduces paracellular permeability ("seals" the gut). BPC-157 is a pentadecapeptide claimed to support angiogenesis, mucosal healing, and tight-junction biology through different (less defined) pathways. Larazotide has phase-3 human trial data; BPC-157 has only animal data and three small pilot human studies. Direct comparisons are not informative.

Is larazotide safe?

Across phase 1–3 trials encompassing thousands of patient-doses, the safety profile is essentially placebo-equivalent. The peptide is locally active in the gut and not measurably absorbed, which limits systemic risk by design. Long-term safety beyond ~6-month trial exposures is not characterized.